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AbstrACt
Introduction Optimal glycaemia can reduce type 2 diabetes 
(T2D) complications. Observing retrospective continuous 
glucose monitoring (r-CGM) patterns may prompt therapeutic 
changes but evidence for r-CGM use in T2D is limited. We 
describe the protocol for a randomised controlled trial (RCT) 
examining intermittent r-CGM use (up to 14 days every three 
months) in T2D in general practice (GP).
Methods and analysis General Practice Optimising 
Structured MOnitoring To achieve Improved Clinical 
Outcomes is a two-arm RCT asking ‘does intermittent r-CGM 
in adults with T2D in primary care improve HbA1c?’
Primary outcome Absolute difference in mean HbA1c 
at 12 months follow-up between intervention and control 
arms. Secondary outcomes: (a) r-CGM per cent time in 
target (4–10 mmol/L) range, at baseline and 12 months; (b) 
diabetes-specific distress (Problem Areas in Diabetes).
Eligibility Aged 18–80 years, T2D for ≥1 year, a (past 
month) HbA1c>5.5 mmol/mol (0.5%) above their 
individualised target while prescribed at least two 
non-insulin hypoglycaemic therapies and/or insulin 
(therapy stable for the last four months). Our general 
glycaemic target is 53 mmol/mol (7%) (patients with a 
history of severe hypoglycaemia or a recorded diagnosis 
of hypoglycaemia unawareness will have a target of 
64 mmol/mol (8%)). Our trial compares r-CGM use and 
usual care. The r-CGM report summarising daily glucose 
patterns will be reviewed by GP and patient and inform 
treatment decisions. Participants in both arms are provided 
with 1 hour education by a specialist diabetes nurse. The 
sample (n=150/arm) has 80% power to detect a mean 
HbA1c difference of 5.5 mmol/mol (0.5%) with an SD of 
14.2 (1.3%) and alpha of 0.05 (allowing for 10% clinic and 
20% patient attrition).
Ethics and dissemination University of Melbourne Human 
Ethics Sub-Committee (ID 1647151.1). Dissemination will be 
in peer-reviewed journals, conferences and a plain-language 
summary for participants.
trial registration number >ACTRN12616001372471; 
Pre-results.
bACkground 
Introduction 
Type 2 diabetes (T2D) is a leading cause of 
disease burden, doubling in prevalence in the 
last 20 years and costing the global community 
strengths and limitations of this study
 ► Our study uses the latest glucose monitoring tech-
nology available to optimise collaborative manage-
ment of type 2 diabetes (T2D) to achieve timely 
intensification of therapy with minimal monitoring 
burden for the person with T2D.
 ► Our pragmatic, individually randomised controlled 
trial will produce robust data about the effectiveness 
of using retrospective continuous glucose monitor-
ing as an adjunct to HbA1c at  3-monthly intervals, 
in primary care.
 ► Our trial is occurring in Victoria, Australia, and so 
may have limited applicability to countries with dif-
ferent primary care systems.
 ► Despite individual randomisation, potential contami-
nation between study arms will be minimised as the 
amount of glucose data available to general practi-
tioners in managing intervention and control group 
participants will differ significantly.
 ► The collection of a range of patient-reported out-
come measures and a planned qualitative study will 
enable robust process evaluation.
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an estimated US$376 billion in 2010.1 Much of this money 
is spent on lowering blood glucose levels and managing 
complications. Achieving and sustaining glycaemic targets 
is important in reducing downstream complications (partic-
ularly microvascular) and all-cause mortality.2 Yet most 
people with T2D do not achieve or sustain target glycated 
haemoglobin (HbA1c—an index of average blood glucose 
level over the preceding 12 weeks),3 despite a growing range 
of available medications.4 Clinical care in general practice 
can help people achieve glycaemic targets,5 through adop-
tion of an evidence-based ‘treat to target’ approach (step-
wise treatment intensification through changes to lifestyle, 
medication doses and/or prescription of additional medi-
cations) as recommended by guidelines internationally.6–8 
A number of factors influence timely treatment inten-
sification.9 These include the knowledge, skills and moti-
vation of both general practitioners (GPs) and people 
with T2D. Both may be concerned by the challenges of 
deciding on and managing complex treatment regimens. 
For GPs, ‘clinical inertia’ may also be fuelled by concerns 
about hypoglycaemia,10 while many people with T2D 
experience ‘psychological insulin resistance’, including 
feelings of failure, to the extent that one in four would be 
unwilling to use insulin if it were recommended.11
Current guidelines base treatment intensification 
recommendations on HbA1c levels,12 13 and several 
studies have determined there are minimal clinical bene-
fits of routine ‘finger-prick’ glucose monitoring.14 15 
Indeed, several countries, including Australia, have now 
restricted the subsidy of blood glucose test strips for 
people with T2D not using insulin.16 However, HbA1c 
alone may not provide sufficient information to guide 
personalised decisions about treatment intensification. 
Identifying day-to-day glucose profiles could supplement 
HbA1c, building both the knowledge and skills of clini-
cians and people with T2D, providing motivation for 
treatment intensification, as well as addressing any under-
lying concerns about risk for hypoglycaemia. Random, 
ad hoc glucose measurements do not provide sufficient 
detail to identify such glucose profiles.16
Manual structured self-monitoring of blood glucose 
(S-SMBG), where people with T2D record blood glucose 
levels intensively over a short period of time (at set times or 
in relation to key moments, eg, pre/post meals or physical 
activity), can enable GPs and people with T2D to identify 
meaningful glucose profiles.17 One trial tested S-SMBG 
used on a 3-monthly basis in people with T2D managed 
in primary care in the USA, identifying clinically signifi-
cant improvements in glycaemia on a per-protocol anal-
ysis,18 accompanied by increased confidence in self-care.19 
However, nearly 50% of participants either withdrew or 
did not adhere to the manual monitoring protocol,18 
suggesting the intensive finger-pricking required (eg, seven 
times per day for three consecutive days) can be a barrier to 
the real-world implementation of S-SMBG. To personalise 
treatment intensification, clinicians and people with T2D 
need a simple, acceptable, feasible, reliable and effective 
method of identifying glucose profiles.
Continuous glucose monitoring (CGM) is another 
method of identifying glucose profiles. CGM involves 
measuring glucose levels continuously using an enzyme-
coated wire or filament inserted into the subcutaneous 
tissue. CGM measures interstitial glucose levels through 
generation of an electrical current when glucose reacts 
with the enzyme glucose oxidase. Until recently, CGM 
technology has calibrated this electrical current to glucose 
levels through finger-prick measurements on several 
occasions during the day. Recent advances in factory-cali-
brated technology mean that finger-prick measurements 
are not needed for some CGM devices. While originally 
licensed only for adjunctive use, increasingly CGM is 
being licensed around the world for making treatment 
decisions, such as adjustment of insulin doses.
CGM can either be used in real time or retrospectively 
(also known as personal or professional modes). Retro-
spective CGM (r-CGM) involves the patient wearing a CGM 
sensor for a period of up to 2 weeks with the glucose data 
downloaded and reviewed retrospectively in collaboration 
with their health professional, to identify day-to-day glucose 
profiles to guide treatment decisions. For many people 
with T2D, glucose profiles tend to be reproducible on a 
day-to-day basis. For these people, intermittent, r-CGM may 
be an appropriate tool for informing management deci-
sions. The use of r-CGM, particularly when no finger-prick 
calibration is involved, minimises the burden of monitoring 
and may overcome a key barrier to engagement. r-CGM 
can also provide detail about hypoglycaemia and hypergly-
caemia, as well as time spent in target range, which are all 
important to clinical and psychosocial outcomes for people 
with T2D.20 Evidence suggests that unrecognised hypogly-
caemia is not uncommon among people with T2D.21 Finally, 
r-CGM can provide insight into glycaemic variability (GV), 
that is, the extent to which glucose fluctuates throughout 
the day. There is growing interest in targeting reduced GV 
as an independent clinical goal with potential to reduce 
complication rates.22
For people with T2D, r-CGM thus offers the prospect 
of an advance in appropriate and personalised care.23 
However, the evidence base for its use in T2D is currently 
limited, with mixed findings. Two trials of real-time CGM 
(ie, unblinded) have been conducted in a select popu-
lation of adults with T2D using multiple daily injections 
of insulin : neither resulted in a clinically significant 
improvement in HbA1c, and while one reduced hypogly-
caemia and improved treatment satisfaction, the other 
did not.24 25 A retrospective matched cohort study did 
identify an improvement in HbA1c associated with use of 
r-CGM (ie, blinded) and called for large-scale prospective 
randomised controlled trials (RCTs) to provide definitive 
evidence.26 A small number of RCTs suggest that r-CGM is 
potentially effective in people with T2D using both insulin 
and non-insulin therapy regimens in achieving glycaemic 
targets. However, these trials are generally small in sample 
size, ranging from 25 to 52 people,27 with short follow-up 
periods of 3–6 months.27 28 A recently published observa-
tional study in India also showed promise in r-CGM for 
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people with T2D, but with only 148 participants, a short 
3-month follow-up period and the possibility of selection 
bias in a non-randomised study, the results need to be 
interpreted with caution.29 Thus, preliminary evidence 
from small RCTs and observational studies suggests the 
potential efficacy of r-CGM in people with non-insu-
lin-treated T2D, but larger adequately powered RCTs are 
needed to study its effectiveness.
Importantly, glucose monitoring, whether manual 
or through new technologies, is not an end in itself. 
Indeed, technology can become burdensome to people 
with T2D.30 Rather, how the information is understood 
and used is central to its utility, and this requires appro-
priate education of both the health professional and the 
person with T2D.30 31 Use of r-CGM needs to be under-
taken collaboratively between patient and GP, with 
support from Credentialed Diabetes Educators (CDE) 
and endocrinologists as appropriate. Active participa-
tion of the person with T2D in this discussion may lead 
to improved understanding and interpretation of glucose 
patterns, informed by the individual’s reflection on their 
lifestyle habits, as well as improving their understanding 
of the rationale for treatment intensification to achieve 
glycaemic targets.31 Indeed, prior research suggests 
that understanding of and engagement with glucose 
patterns among people with T2D may be a facilitator of 
treatment intensification.19 32 Both the GP and person 
with T2D need training to interpret the data, to work 
collaboratively to plan lifestyle or medication changes 
and set appropriate goals. The person with T2D needs 
the behavioural skills to make changes to self-manage-
ment, and GPs need to work in partnership with them 
to support self-management. To do so, GPs also need to 
understand the importance of glycaemic targets and have 
the skills and confidence to interpret glucose patterns, 
make appropriate treatment changes and have collabora-
tive discussions with the patient about active self-manage-
ment of T2D. None of the studies outlined above include 
substantial educational components of this nature.
Aim and research questions
Our aim is to conduct an individually RCT to examine 
the effectiveness of the intermittent use of r-CGM in the 
management of T2D in general practice, and specifically 
to test the effect of r-CGM on achieving glycaemic targets.
Our research questions are
1. Does the judicious use of intermittent r-CGM in peo-
ple with T2D in primary care improve glycaemic con-
trol as measured by HbA1c?
2. Is intermittent r-CGM cost-effective?
MEthods And AnAlysIs
study design
GP-OSMOTIC is a two-arm individually RCT in general 
practice comparing collaborative use of r-CGM to usual 
care in people with T2D whose HbA1c is above recom-
mended target, despite prescription of at least two 
non-insulin hypoglycaemic agents and/or insulin. The 
study design is outlined in the Consolidated Standards 
of Reporting Trials (CONSORT) diagram (figure 1). 
Reporting will follow CONSORT guidelines for RCTs.33 34
Participant recruitment and randomisation procedures
Practices with at least one consenting GP are eligible. 
Practices will be approached from a database of research 
and teaching active practices associated with the Depart-
ment of General Practice at the University of Melbourne.
Eligible patients will be aged 18–80 years, active 
patients of the practice (defined as three or more visits 
to the practice in the past two years), have had T2D 
for at least 1 year with their most recent HbA1c (in the 
previous one month)≥5.5 mmol/mol (0.5%) above their 
individualised target (see below), while prescribed at 
least two non-insulin hypoglycaemic agents as therapy 
and/or insulin (therapy stable for the past four months). 
Our general glycaemic target is set at 53 mmol/mol 
(7%), while those with a history of severe hypoglycaemia 
(requiring assistance from a third person for recovery) 
or a recorded diagnosis of hypoglycaemia unawareness 
will have a target of 64 mmol/mol (8%), consistent with 
Australian guidelines.35 In the setting of this pragmatic 
trial, we will allow GPs to indicate a personalised target 
Figure 1 Study Consolidated Standards of Reporting 
Trials design. GP, general practitioner; r-CGM, retrospective 
continuous glucose monitoring; RN-CDE, Registered Nurse-
Credentialed Diabetes Educator; T2D, type 2 diabetes. 
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for a participant if they feel that it should differ from the 
two prespecified targets set out above.
Patient exclusion criteria will include any debilitating 
medical condition (eg, unstable cardiovascular disease, 
severe mental illness, end-stage cancer), an electronic 
Glomerular Filtration Rate <30; proliferative retinopathy, 
pregnancy, lactating or planning pregnancy, unable to 
speak English/give informed consent, unwilling to use 
r-CGM or follow study protocol, allergy to adhesive tape, 
any condition that makes monitoring of glucose control 
using HbA1c unreliable (eg, haemoglobinopathy, iron 
deficiency anaemia).
Practices that agree to participate will be asked to 
generate a list of potentially eligible patients to be 
screened for full eligibility by searching their practice 
electronic medical record database. Patients will then be 
invited by letter and/or telephone call to attend the prac-
tice to hear more about the study and give consent. At 
this visit, a clinically trained research assistant will explain 
the study and, if the patient consents, collect baseline 
demographic, clinical, biometric and psychometric data 
and arrange baseline pathology tests. Study data will be 
collected and managed using REDCap36 electronic data 
capture tools hosted at the University of Melbourne. Final 
eligibility will be confirmed based on the baseline HbA1c.
The remaining list of consenting eligible participating 
patients will be randomly allocated to intervention or 
control using an electronic radio-button in REDCap. 
Electronic contact is made with an allocation schedule 
developed and held at the University of Melbourne 
Department of General Practice. Patients will not be allo-
cated until after study consent is obtained, baseline data 
collected, eligibility confirmed and baseline r-CGM trace 
is started (ie, sensor attached). Participant timeline is 
provided as online supplementary appendix 1.
We will use block randomisation at the practice level, 
that is, block randomisation sequences of 4 and 6 will 
be computer generated by the study statistician for each 
practice who participate and individual participating 
patients at each practice site will be randomised.
Participant recruitment commenced in October 2016 
and was completed in October 2017. Final 12-month 
follow-up is anticipated to be completed in October 2018.
Intervention description
The General Practice Optimising Structured MOnitoring 
To achieve Improved Clinical Outcomes (GP-OSMOTIC) 
intervention is informed by the existing evidence for 
structured SMBG20 37 and our understanding that the 
effective application of glucose monitoring is just one 
aspect of a complex behavioural intervention, including 
but not limited to clinician/patient agreement and moti-
vation for monitoring; establishment of glucose targets 
and parameters for monitoring (timing/frequency/ dura-
tion); interpretation of glucose patterns; action planning 
(for how to intervene to improve glucose levels); action 
(eg, changing food/drink, physical activity and/or medi-
cation); and monitoring and reflection.38 Drawing on 
this literature, health professionals will be encouraged to 
employ our ‘Check, Chat, Change (repeat)’ framework 
within the consultation with intervention participants 
with T2D (table 1). This framework aims to build motiva-
tion, confidence and skills of participating health profes-
sionals and people with T2D in the collaborative use of 
r-CGM, interpretation of glucose patterns and interven-
tion to improve glucose levels.
The desired ‘Check, Chat, Change’ training compo-
nents and outcomes described in table 1 are delivered 
via a 2 hour training session, for all participating GPs and 
practice nurse (PN), either on site at the practice or via 
an online video recording of the training. The training 
is delivered by a GP with a special interest in T2D and 
a Registered Nurse-Credentialed Diabetes Educator 
(RN-CDE) with minimum 5 years’ experience. The 
training content is developed by the GP and RN-CDE, 
with input from health psychologists with expertise in 
diabetes self-management and education (JS and JB). 
Throughout the training session, GPs and PNs will have 
opportunity to reflect on their attitudes towards glucose 
monitoring in T2D, test their knowledge about how to 
apply the r-CGM device, review r-CGM trace data and 
identify suitable treatment change options.
Participating people with T2D randomised to the inter-
vention arm will attend an individual face-to-face diabetes 
education session of 60 min with the study RN-CDE. 
This will be held on site at the patient's general practice. 
This session will include instruction on how to wear the 
r-CGM device and how to interpret the glucose reports 
from the device to better understand their blood glucose 
and how this relates to their diabetes self-management 
and treatment options. Brief supportive information 
about the device and about diabetes self-management (as 
commonly provided in diabetes education sessions) will 
be provided to patients by the GP clinic staff and the study 
CDE. Participating GPs also have the opportunity to sit in 
and observe this session with the first patient randomised 
to the intervention arm.
Intervention participants will be asked to wear the 
r-CGM device for a period of 2 weeks every three months, 
that is, at baseline, 3, 6, 9 and 12 months, as well as having 
an HbA1c taken at those times, and to attend a consul-
tation with their GP and discuss the r-CGM reports. This 
3-monthly interval is consistent with clinical practice 
guidelines about regular, stepwise consideration of treat-
ment intensification. The r-CGM device will be applied at 
those 3-monthly intervals at the GP clinic (ie, by the GP or 
PN who have attended the health professional training). 
Patients and practices will be sent reminders to undertake 
this 3-monthly monitoring.
Those randomised to the control group will wear the 
r-CGM device at baseline but the data will be blinded 
to both the patient participant and their GP. They 
will continue to receive usual clinical care. Both GP 
and patient will, however, be prompted to undertake 
3-monthly diabetes reviews consistent with clinical prac-
tice guidelines about regular stepwise consideration of 
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treatment intensification. Participants randomised to the 
control group will also attend an education session with a 
local CDE (funded by the study if necessary to eliminate 
financial barriers). We will assist with scheduling this for 
control group.
Regardless of the study arm to which their patients are 
randomised, the GP will be free to refer to or consult with 
an endocrinologist, CDE or any other appropriate health 
professional, as part of their usual clinical practice.
r-CgM device to be used in the study
The r-CGM device being used in the study is the Abbott 
FreeStyle Libre Pro Flash Glucose Monitoring System. The 
system has three parts: a hand-held reader, a disposable 
sensor and associated software. The sensor is applied 
to the upper arm of the person with T2D by the health 
professional (eg, GP or PN) and activated using the 
reader. The sensor is worn by the person with T2D for up 
to 14 days, over which time it records interstitial glucose 
levels every 15 min, though these readings are not visible 
to the person wearing the sensor. No additional finger-
prick calibration is needed. At any time, the person can 
return to their health professional to have data from 
the sensor uploaded via the reader to software on a 
computer, although at least 5 days of data is needed to 
generate meaningful output.39 40 Using the reader, the 
health professional downloads the glucose data from the 
sensor in the form of reports summarising daily patterns 
of glucose levels, called an ‘ambulatory glucose profile’ 
(AGP). These are then used to identify glucose patterns, 
including hypoglycaemia, hyperglycaemia, time in range 
and GV.
Evaluation of the AGP output and guidelines for its 
interpretation have been published elsewhere.39 40
outcomes
Our primary outcome measure is the absolute difference 
in mean HbA1c at 12 months between the intervention 
and control arm.
Our secondary outcome measures are (a) per cent 
time in target (4–10 mmol/L) range, assessed via r-CGM 
device; and (b) diabetes-specific distress as measured by 
the Problem Areas in Diabetes (PAID) scale.41
Our hypotheses are that
1. The absolute difference in mean HbA1c at 12 months 
between the intervention and control arm will 
be ≥0.5%, favouring the intervention arm.
2. Glucose time in target (%) will favour the intervention 
arm.
3. No difference in diabetes-specific distress (mean PAID 
scores) will be observed at 12 months between inter-
vention and control arm.
4. Cost effectiveness will favour the intervention arm.
Other r-CGM outcomes will include per cent time 
below target range (<4.0 mmol/L) and very low 
(<3.0 mmol/L) range (level 1 and level 2 hypogly-
caemia42) and per cent time in high (>10.0 mmol/L) and 
very high (>15.0 mmol/L) range; GV as reflected by SD 
and Mean Amplitude of Glucose Excursions; per cent of 
r-CGM trace available for 14 days. Other clinical measures 
Table 1 The ‘Check, Chat, Change’ framework and training elements
Target outcome/behaviour Health professional training
Check GP understanding of evidence for effective 
and timely assessment of blood glucose 
and using r-CGM
Effective and timely assessment of blood 
glucose using r-CGM
Engagement of person with T2D in 
collaborative consultation
Present evidence and rationale for treatment intensification
Present information about and demonstrate (model) how 
to apply/remove sensors, download and interpret r-CGM 
data; support person with T2D in correct use of r-CGM as a 
complement to usual care and testing
Demonstrate (model) collaborative engagement of person 
with T2D in use of r-CGM
Chat Collaborative reflection on and 
interpretation of recurring glucose patterns, 
and the effect of food/drink, physical 
activity and medication
Present information about how to read and interpret r-CGM 
patterns
Demonstrate interpretation of r-CGM patterns by GP and 
RN-CDE using case studies
Demonstrate (model) collaborative engagement of person 
with T2D in the interpretation of r-CGM, supporting them to 
interpret glucose patterns, identifying hyperglycaemia and 
hypoglycaemia and impact of lifestyle and medications on 
glucose levels
Change Identify appropriate intervention to improve 
blood glucose and engage person with 
T2D in action planning
Present evidence (clinical guidelines) for intensification of 
lifestyle, OHA, injectable medications in response to r-CGM
Demonstrate (model) collaborative discussion of potential 
change in management of T2D and agreement on action 
plan
Repeat the cycle Observe and reflect on the effectiveness of changes made at the next visit
GP, general practitioner; OHA, Oral Hypoglycaemic agent; r-CGM, retrospective continuous glucose monitoring; RN-CDE, Registered Nurse-
Credentialed Diabetes Educator; T2D, type 2 diabetes.
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include recording of the behavioural change recommen-
dations made, medication changes prescribed, weight 
and height. Other psychological outcomes are detailed 
in table 2.
blinding
Participants in the intervention arm will be able to see 
their baseline r-CGM tracing as part of their baseline 
clinic assessment visit, while those randomised to the 
control arm will not have access to their baseline CGM 
tracing. The final 12-month tracing will be available to 
participants in both arms (following final data collec-
tion), enabling the GP and PN to use that as part of clin-
ical management for all study participants.
data collection, management and analysis
Collection of clinical, biometric and psychosocial data is 
summarised in table 2.
Qualitative exploration of experience with and 
perceived impact of r-CGM and the collaborative care 
decision-making model will be explored at the end of the 
study in semistructured interviews with a sample of GPs/
PNs (~N=10) and intervention participants (~N=20), with 
stratification based on participant characteristics and 
outcomes. We will explore usability and acceptability of 
the intervention, confidence in r-CGM, perceived impact 
of r-CGM (on glucose levels, diabetes management, 
quality of life), and perceived advantages and disadvan-
tages of r-CGM and the collaborative care model. Inter-
views will be audio-recorded, transcribed and the data will 
be subjected to thematic analysis.
Health service utilisation will be obtained from relevant 
Victorian and Australian datasets. Participants have the 
option to also consent to provide a blood sample for use 
in an ancillary study of epigenetic markers associated with 
GV (see online supplementary appendix 2).
Power calculation, sample size and data analysis
Based on an individually RCT, stratified by practice, the 
sample size has 80% power to detect a difference in 
mean HbA1c of 5.5 mmol/mol (0.5%) with an SD of 14.2 
(1.3%)43 and an alpha of 0.05. The required number 
of participants in each arm is n=108, a total of n=216. 
Assuming a 20% attrition rate, this inflates to n=270 
(n=135 in each arm). Allowing for 10% clinic attrition and 
assuming six participants per clinic, we are thus aiming to 
recruit n=300 participants (n=150 in each arm).
Clinic, GP and patient characteristics at baseline will be 
summarised for each study group and assessed for imbal-
ance. Mean HbA1c levels at baseline and 12 months will 
be plotted for each study arm.
A linear mixed-effects model (ie, with both fixed effect 
for treatment and time and random effect for clinic and 
repeated patient HbA1c measurements) will be used to 
estimate the group difference in HbA1c at 12 months 
using restricted maximum likelihood estimation. The 
model will include the HbA1c at baseline, 6 months and 
12 months and be adjusted by age and history of hypogly-
caemia should these be imbalanced between the arms at 
baseline. A secondary analysis will examine whether the 
intervention effect differs between those with and without 
a history of severe hypoglycaemia. The same approach 
Table 2 Details and timing of data collection
Measures
Month
 0 3 6 9 12
Clinical Rx, comorbidity x x
Behavioural change recommendations made; Rx changes 
prescribed
x x x x
Biometric Weight, height x x
Glycaemia HbA1c x x x
Other path Lipids, creatinine, spot urine albumin–creatinine ratio x x
r-CGM AGP x x* x* x* x
Psycho-social  ► Diabetes distress: Problem Areas in Diabetes scale41
 ► Satisfaction with and user experience of glucose monitoring: 
Glucose Monitoring Experience Questionnaire49
 ► General Emotional Well-being: WHO (five) Well-being Index50
 ► Hypoglycaemia frequency and severity: selected items from the 
Hypoglycaemia Awareness Questionnaire51
 ► Diabetes-specific quality of life: DAWN Impact of Diabetes 
Profile 52
 ► Health status: EuroQoL 5 Dimensions 53
 ► Summary of Diabetes Self-care Activities 54
 ► Perceived involvement in Self-Care scale55
x x
*Data collected for intervention arm only.
AGP, ambulatory glucose profile; r-CGM, retrospective continuous glucose monitoring. 
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will be used to determine whether the intervention effect 
varies for those with a general HbA1c target compared 
with those with a personalised HbA1c target.
Analysis will be based on an intention-to-treat approach. 
Mixed models assume any missing data are missing at 
random. Hence, sensitivity analyses will be conducted to 
assess the robustness of this assumption. A full statistical 
analysis plan for the trial will be published separately.
We will use the United Kingdom Prospective Diabetes 
outcomes simulation model (with updated Australian 
equations where possible) to perform economic evalu-
ation.44 The impact of diabetes on morbidity, mortality, 
health status and healthcare costs will be estimated for 
each arm during the trial period and beyond using a 
model based on risk factors and complications. Health 
status impacts for the two arms will be incorporated 
using EQ5D weights to allow estimation of cost utility. 
The model allows extrapolation from the trial outcomes 
to downstream events and complications, including esti-
mation of the long-term impact of changes in disease 
management. Costs of monitoring and education will be 
sourced from trial administrative databases. In addition, 
costs associated with the health states (eg, stroke, heart 
disease) will be obtained from relevant Victorian and 
Australian data sets. The results of the economic model-
ling will be presented as incremental cost per quality-ad-
justed life-year (QALY) gained at trial conclusion and full 
life expectancy for the r-CGM arm relative to the control 
arm.
Monitoring
We will collect data on the fidelity of the intervention (if 
GPs have undertaken the training in r-CGM use and inter-
pretation and adherence to the 3-monthly visits through 
collection of Clinic Assessment Visit (CAV) forms, which 
also ask if any technical problems have been encoun-
tered in relation to the sensor, including local skin reac-
tions). Adverse events may also be reported at CAVs and 
are collected at follow-up data collection using standard 
operating procedures. A safety monitoring committee 
consisting of one GP, one RN-CDE and one endocrinolo-
gist will be appointed to review significant adverse events, 
which includes any episodes of severe hypoglycaemia, 
and their duration, treatment and outcome.
Patient and public involvement
Patients and/or public were not involved in the develop-
ment of the research question and outcome or the design 
of this study.
Ethics and dissemination
Ethics approval has been obtained from the Univer-
sity of Melbourne Health Sciences Human Ethics Sub 
Committee (Ethics ID 1647151.1). All participating 
health professionals and people with T2D will sign a 
consent form prior to participating. We will disseminate 
the results in peer-reviewed journals, presentations at 
scientific meetings and will also provide a plain language 
summary to study participants. Data will be retained in 
secure storage at the University of Melbourne in accor-
dance with National Health and Medical Research 
Council (NHMRC) Guidelines.
dIsCussIon
Our proposal tackles an important clinical problem 
with significant health and cost implications for the 
1.1 million Australians with T2D in primary care, half 
of whom have glycaemic levels above recommended 
target range. While we chose an evidence-based, clin-
ically meaningful primary outcome (HbA1c), our trial 
is based on the premise that novel glucose monitoring 
technologies provide a potential tool for GPs and 
people with T2D to visualise blood glucose patterns 
clearly, enabling them to make evidence-based and 
personalised treatment choices and plans to achieve 
optimal glycaemic targets. Below we discuss the key 
innovative features of our study design.
We are conducting a pragmatic, individually RCT as 
it will produce robust data about the true effect of our 
intervention. We will train all GPs to use and interpret 
the results of r-CGM, while only half of their partici-
pating patients will be using the technology as part of 
clinical care. The amount of glucose data available to 
GPs in managing intervention and control group partic-
ipants will thus differ significantly. GPs’ confidence and 
clinical skills in T2D management may be enhanced 
(in relation to treatment intensification, built through 
seeing the glucose profiles of people with T2D and the 
effect of medication and lifestyle changes in interven-
tion participants). However, we do not believe signifi-
cant contamination between arms is likely to occur as 
the application of any news skills in the control arm 
will be limited by lack of access to detailed, person-
alised glucose profiles, which will not be available 
for control group participants. The 3-monthly review 
prompts and the 1 hour Diabetes Educator session will 
be standardised exposures across both arms, enabling 
us to isolate the effect of the r-CGM device used in 
the intervention group. We chose usual care as our 
comparator group as s-SMBG is not currently routine 
practice in Australia and does not feature in current 
NHMRC or Royal Australian College of General Practi-
tioners (RACGP) guidelines.45
Personalised use of self-monitoring devices is a 
burgeoning and rapidly changing field. Automated 
and seamless data collection and presentation is a crit-
ical factor in the usability of such technology. We chose 
a retrospective, professionally held CGM technology 
for several reasons. This first is that people with T2D 
have relatively stable and simple glucose profiles on a 
day-to-day basis.46 This contrasts with people with T1D 
who have more unpredictable glucose profiles with 
more GV. Thus, people with T1D need real-time glucose 
data while people with T2D can learn much about their 
own glucose profiles and the effects of medication 
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and behaviours from retrospective data, and then use 
that to effect self-management changes. Based on our 
experience and understanding of the general practice 
setting, we expect that the clinical use of r-CGM would 
fit well with existing patterns of clinical practice. Inser-
tion of a sensor is done relatively quickly by either the 
GP or PN. At a scheduled follow-up appointment, the 
sensor data can be uploaded easily and viewed in a 
regular consultation with a GP, and the report format 
enables easy visualisation and collaborative discussion 
of tangible self-management changes between the GP 
and the person with T2D.
There are now several r-CGM devices available in 
the Australian market. This study is investigator-initi-
ated, funded by the Australian National Health and 
Medical Research Council, and the investigator group 
has no commercial interest with the manufacturer of 
these devices. However, we structured our study around 
the use of an automated device requiring no finger-
prick calibration as we believe this is the most likely 
form and direction that the technology will take in the 
future, with minimal burden on the person with T2D 
addressing a key barrier to S-SMBG levels.
Our study embeds r-CGM technology within a 
supportive and collaborative educational framework 
for the GP and PN and the person with T2D. r-CGM 
needs to be integrated within an educational inter-
vention that promotes and supports patient engage-
ment with possible behavioural changes and treatment 
adjustments.
Hypoglycaemia, and in particular nocturnal hypogly-
caemia, in people with T2D is significant but commonly 
under-reported in RCTs (especially in in those on 
insulin)47 and elsewhere.48 As a pragmatic real-world 
study, our trial also offers a unique opportunity to 
gather robust data on the prevalence of hypoglycaemia 
among a primary care T2D population.
Limitations of our study are that no independent 
monitoring has been performed and that serious 
adverse events were not structurally assessed (ie, 
reporting was dependent on the clinicians at the partic-
ipating practices).
Our study will provide important evidence of the 
effectiveness of new r-CGM technologies as they inev-
itably enter the community, enabling rational clinical 
and health policy decisions, potentially shaping T2D 
clinical practice in Australia and around the world, 
with impact on health and healthcare costs.
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